분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-09-01 09:44:52 , Hit : 689
 First CAR T-Cell Therapy Approved in U.S.

The Scientist »
The Nutshell

http://www.the-scientist.com/?articles.view/articleNo/50231/title/First-CAR-T-Cell-Therapy-Approved-in-U-S-/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=55843454&_hsenc=p2ANqtz-9X__FTJkvm1fbmiaGryJQJBBTqBqgFAYu4aL3cWVIz1oRoLd2CUGqUWRLFb7t17z8OXYx1oIdhYo4QTd_VIwIZArL3EA&_hsmi=55843454/


The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

By Shawna Williams | August 30, 2017


Each patient’s T-cells will be harvested from the body and genetically programmed to target leukemia cells.


The US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist of a patient’s own white blood cells, harvested from the body and genetically programmed to seek an antigen on the surface of leukemia cells.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” says FDA Commissioner Scott Gottlieb in a statement. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

Kymriah is approved for patients 25 years old and younger who have B-cell acute lymphoblastic leukemia, and whose disease has relapsed at least twice or is still detectable after other treatment. In a clinical trial, the therapy left 83 percent of such patients cancer-free after three months. STAT notes that only a few hundred patients per year may be eligible for the cell therapy. Priced at $475,000, it will be offered at just 32 sites around the country.

See “The CAR T-Cell Race”

Despite the limited use of Kymriah, the approval ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases,” FDA says. Business Insider reports that at an FDA meeting last month, oncologist Tim Cripe of Nationwide Children’s Hospital called Kymriah “the most exciting thing I’ve seen in my lifetime.”







1047   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 485
1046   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 686
1045   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 568
1044   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 608
1043   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 665
1042   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 640
1041   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 555
1040   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 499
1039   To Speed CRISPR/Cas9’s Search and Snip, Try Extra Cas9 and gRNA  이성욱 2017/09/30 1989
1038   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 505
1037   Mutations Making CRISPR Hyper-Accurate Discovered  이성욱 2017/09/22 853
1036   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 582
1035   Alcoholism Gene Therapy Shows Promise  이성욱 2017/09/20 582
1034   DNA Construction  이성욱 2017/09/15 660
1033   Cargo-Sorting DNA Robots  이성욱 2017/09/15 1139
1032   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 604
1031   Outsourcing Gene Editing to the Public-Online Game Challenges Players to Design CRISPR On/Off Switch  이성욱 2017/09/05 722
1030   Scientists Doubt Results of CRISPR’d Embryos  이성욱 2017/09/02 539
1029   Scientists Look to Epigenetics to Thwart Viruses  이성욱 2017/09/02 709
  First CAR T-Cell Therapy Approved in U.S.  이성욱 2017/09/01 689

[이전 10개] [1]..[11] 12 [13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN